drugset / Trial / NCT01150981

Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

NCT01150981

RandomizedParallel-groupTriple-blindBasic science

Summary

Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this research is to see if rosiglitazone also increases blood vessel growth in human fat cells. The investigators will compare results from before and after being on rosiglitazone for 6 weeks.

Timeline

Start
2006-11
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 8 mg Oral

Indications